AR059097A1 - Tratamiento a largo plazo de la infeccion por vih - Google Patents
Tratamiento a largo plazo de la infeccion por vihInfo
- Publication number
- AR059097A1 AR059097A1 ARP070100247A ARP070100247A AR059097A1 AR 059097 A1 AR059097 A1 AR 059097A1 AR P070100247 A ARP070100247 A AR P070100247A AR P070100247 A ARP070100247 A AR P070100247A AR 059097 A1 AR059097 A1 AR 059097A1
- Authority
- AR
- Argentina
- Prior art keywords
- long
- hiv infection
- term treatment
- formulation
- treatment
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 238000011866 long-term treatment Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de una formulacion parenteral que comprende una cantidad efectiva como anti-viral de TMC278 o una sal de adicion de ácido farmacéuticamente aceptable del mismo, y un portador, para la elaboracion de un medicamento para el tratamiento de un sujeto infectado con VIH, en donde la formulacion se va a administrar de modo intermitente en un intervalo de tiempo de al menos una semana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100677 | 2006-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059097A1 true AR059097A1 (es) | 2008-03-12 |
Family
ID=36446113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100247A AR059097A1 (es) | 2006-01-20 | 2007-01-19 | Tratamiento a largo plazo de la infeccion por vih |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | USRE50189E1 (es) |
| EP (1) | EP1981506B3 (es) |
| JP (2) | JP5754005B2 (es) |
| KR (2) | KR101501475B1 (es) |
| CN (2) | CN103877091A (es) |
| AP (1) | AP2936A (es) |
| AR (1) | AR059097A1 (es) |
| AU (1) | AU2007206901B2 (es) |
| BR (1) | BRPI0707179A2 (es) |
| CA (1) | CA2636436C (es) |
| CY (1) | CY1114089T1 (es) |
| DK (1) | DK1981506T6 (es) |
| EA (1) | EA014914B1 (es) |
| ES (1) | ES2414982T7 (es) |
| HR (1) | HRP20130544T4 (es) |
| IL (1) | IL192132A (es) |
| ME (1) | ME01617B (es) |
| MY (1) | MY150717A (es) |
| NZ (1) | NZ569347A (es) |
| PL (1) | PL1981506T6 (es) |
| PT (1) | PT1981506E (es) |
| RS (1) | RS52821B2 (es) |
| SG (1) | SG170073A1 (es) |
| SI (1) | SI1981506T1 (es) |
| TW (1) | TWI458483B (es) |
| UA (1) | UA96436C2 (es) |
| WO (1) | WO2007082922A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| TWI457136B (zh) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| RS52821B2 (sr) | 2006-01-20 | 2021-07-30 | Janssen Sciences Ireland Unlimited Co | Dugotrajno tretiranje hiv-infekcije sa tcm278 |
| AU2014200819B2 (en) * | 2006-06-23 | 2016-05-26 | Janssen Sciences Ireland Uc | Aqueous suspensions of TMC278 |
| HUE038797T2 (hu) * | 2006-06-23 | 2018-11-28 | Janssen Sciences Ireland Uc | TMC278 vizes szuszpenziói |
| AU2016219555B2 (en) * | 2006-06-23 | 2017-08-10 | Janssen Sciences Ireland Uc | Aqueous suspensions of TMC278 |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| EP2381961B1 (en) * | 2008-12-24 | 2016-09-14 | Janssen Sciences Ireland UC | Implantable devices for treating hiv |
| PL2480220T3 (pl) * | 2009-09-22 | 2015-10-30 | Janssen Sciences Ireland Uc | Leczenie i zapobieganie zakażeniu HIV |
| MY163383A (en) * | 2009-12-21 | 2017-09-15 | Janssen Sciences Ireland Uc | Degradable removable implant for the sustained release of an active compound |
| PH12012501537A1 (en) | 2010-01-27 | 2018-02-07 | Viiv Healthcare Co | Antiviral therapy |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| US9266824B2 (en) | 2014-01-13 | 2016-02-23 | Warsaw Orthopedic, Inc. | Methods and compositions for making an amino acid triisocyanate |
| US10406098B2 (en) * | 2015-11-16 | 2019-09-10 | Evonik Roehm Gmbh | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
| US20190163877A1 (en) * | 2017-11-27 | 2019-05-30 | International Business Machines Corporation | Decision support for effective long-term drug therapy |
| WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
| JP2003509453A (ja) | 1999-09-21 | 2003-03-11 | アールティーピー・ファーマ・インコーポレーテッド | 生物学的に活性な物質の、表面改質された粒状組成物 |
| HUP0302631A2 (hu) | 2000-03-30 | 2003-11-28 | Bristol-Myers Squibb Co. | Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék |
| US20040115268A1 (en) | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AU2002364701B8 (en) | 2001-11-20 | 2006-06-22 | Alkermes, Inc. | Compositions for sustained action product delivery |
| US6568805B1 (en) * | 2001-11-26 | 2003-05-27 | Dan L. Dietz Trust | Magnetic buckle for eyeglasses |
| US7094413B2 (en) * | 2002-01-24 | 2006-08-22 | Sangstat Medical Corporation | Combined therapy for treatment of HIV infection |
| ATE361059T1 (de) | 2002-11-08 | 2007-05-15 | Glaxo Group Ltd | Antivirale zusammensetzungen |
| AU2003282883B2 (en) | 2002-11-18 | 2008-12-04 | Polaris Group | Methods for inhibiting viral replication in vivo |
| CL2004000192A1 (es) | 2003-02-07 | 2005-03-18 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. |
| JP2006518373A (ja) | 2003-02-21 | 2006-08-10 | トリペップ アクチ ボラゲット | Ｈｉｖ複製を抑制するためのグリシンアミド誘導体 |
| SI1632232T1 (sl) * | 2004-09-02 | 2011-09-30 | Janssen Pharmaceutica Nv | Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila |
| PL1632232T6 (pl) * | 2004-09-02 | 2022-06-27 | Janssen Pharmaceutica Nv | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu |
| ES2526092T3 (es) | 2004-11-16 | 2015-01-05 | Alkermes Pharma Ireland Limited | Formulaciones de olanzapina en nanopartículas inyectables |
| TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| RS52821B2 (sr) | 2006-01-20 | 2021-07-30 | Janssen Sciences Ireland Unlimited Co | Dugotrajno tretiranje hiv-infekcije sa tcm278 |
| HUE038797T2 (hu) | 2006-06-23 | 2018-11-28 | Janssen Sciences Ireland Uc | TMC278 vizes szuszpenziói |
| ES2437331T3 (es) | 2007-07-12 | 2014-01-10 | Janssen R&D Ireland | Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo |
-
2007
- 2007-01-19 RS RS20130258A patent/RS52821B2/sr unknown
- 2007-01-19 ME MEP-2013-66A patent/ME01617B/me unknown
- 2007-01-19 PL PL07712053T patent/PL1981506T6/pl unknown
- 2007-01-19 EP EP07712053.3A patent/EP1981506B3/en active Active
- 2007-01-19 SG SG201101585-6A patent/SG170073A1/en unknown
- 2007-01-19 AP AP2008004535A patent/AP2936A/xx active
- 2007-01-19 PT PT77120533T patent/PT1981506E/pt unknown
- 2007-01-19 WO PCT/EP2007/050516 patent/WO2007082922A2/en not_active Ceased
- 2007-01-19 US US17/473,424 patent/USRE50189E1/en active Active
- 2007-01-19 AR ARP070100247A patent/AR059097A1/es not_active Application Discontinuation
- 2007-01-19 MY MYPI20082697 patent/MY150717A/en unknown
- 2007-01-19 DK DK07712053.3T patent/DK1981506T6/da active
- 2007-01-19 AU AU2007206901A patent/AU2007206901B2/en active Active
- 2007-01-19 TW TW096101983A patent/TWI458483B/zh active
- 2007-01-19 KR KR1020087018888A patent/KR101501475B1/ko active Active
- 2007-01-19 CN CN201410126123.XA patent/CN103877091A/zh active Pending
- 2007-01-19 ES ES07712053T patent/ES2414982T7/es active Active
- 2007-01-19 KR KR1020147030400A patent/KR101562943B1/ko active Active
- 2007-01-19 UA UAA200809750A patent/UA96436C2/ru unknown
- 2007-01-19 JP JP2008550764A patent/JP5754005B2/ja active Active
- 2007-01-19 EA EA200870183A patent/EA014914B1/ru unknown
- 2007-01-19 US US12/161,445 patent/US10953009B2/en not_active Ceased
- 2007-01-19 BR BRPI0707179-5A patent/BRPI0707179A2/pt not_active Application Discontinuation
- 2007-01-19 HR HRP20130544TT patent/HRP20130544T4/hr unknown
- 2007-01-19 CA CA2636436A patent/CA2636436C/en active Active
- 2007-01-19 NZ NZ569347A patent/NZ569347A/en unknown
- 2007-01-19 CN CNA2007800024269A patent/CN101370504A/zh active Pending
- 2007-01-19 SI SI200731253T patent/SI1981506T1/sl unknown
-
2008
- 2008-06-12 IL IL192132A patent/IL192132A/en active IP Right Grant
-
2013
- 2013-01-28 JP JP2013013118A patent/JP5836983B2/ja active Active
- 2013-06-27 CY CY20131100521T patent/CY1114089T1/el unknown
-
2021
- 2021-03-01 US US17/188,850 patent/US20210177843A1/en not_active Abandoned
-
2023
- 2023-08-22 US US18/236,734 patent/US20240226099A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059097A1 (es) | Tratamiento a largo plazo de la infeccion por vih | |
| AR061620A1 (es) | Suspensiones acuosas de tmc278 | |
| BRPI1013394A2 (pt) | "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c." | |
| CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
| CL2008003406A1 (es) | Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih. | |
| UY29868A1 (es) | Nucleocidos 4 modificados como agentes antivirales | |
| UA114351C2 (uk) | Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування | |
| CL2011002878A1 (es) | Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih. | |
| CL2009002206A1 (es) | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. | |
| CL2014001585A1 (es) | Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih. | |
| CL2013000727A1 (es) | Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c. | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| CL2012001080A1 (es) | Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida. | |
| CL2013000715A1 (es) | Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih. | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| BRPI1012666B8 (pt) | cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso | |
| AR078283A1 (es) | Formulaciones de suspension oral de dibenzazepina carboxamidas | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| BR112016005417A8 (pt) | "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos" | |
| MX2021008248A (es) | Composicion farmaceutica. | |
| AR052165A1 (es) | Tratamiento de hepatitis c en la poblacion asiatica | |
| UA90124C2 (ru) | Способ профилактики вич-инфекции с помощью тмс278 | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |